Given the increasing frequency of hematologic malignancies and the complexities of treatments with novel agents, particularly with immunotherapeutic approaches, there is a need to provide an opportunity for oncologists, hematologists, oncology nurses and pharmacists to engage in thoughtful discussions with experts in these fields. In addition, there is emerging data about the biology of these malignancies impacting optimal management of patients with these disorders. Clinical decision making and management therefore have become more complex.

This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of leukemia, lymphoma, multiple myeloma and stem cell transplantation by novel immunotherapies and treatment combinations. Updates on evolving immunologically and molecular based system therapies will be profiled and discussed.

Learning Objectives

Upon completion of this symposium, participants should be better able to:

• Summarize the evolving therapeutic strategies in the treatment of hematologic malignancies.
• Provide an update of new molecular and immunological treatments being developed for these diseases.
• Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia.
• Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options.

Who Should Attend

This symposium is directed toward hematologists, oncologists, pathologists, radiation oncologists, palliative care staff, oncology, hematology nurses, laboratory personnel, pharmacists and other allied health care team members interested in the treatment of patients with hematologic malignancies.

Symposium Directors

Guenther Koehne, M.D., Ph.D.
Deputy Director
Chief, Blood and Marrow Transplant and Hematologic Oncology
Miami Cancer Institute
Miami, Florida

Disclosure Policy and Disclaimer